Bausch + Lomb to Present New Data on Products and Pipeline Programs at ARVO

Bausch + Lomb announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.

The presentations include results from the 12-month KALAHARI safety extension study of the investigational treatment NOV03 (perfluorohexyloctane), as well as the results of two studies on surgical intraocular lens pipeline programs. Another presentation will focus on the early adoption of Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use by providers, and two others will feature a data analysis from Bausch + Lomb’s Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study.

“At this year’s ARVO meeting, scientists will present a variety of clinical research on our Bausch + Lomb product portfolio, pipeline programs and the latest results from our unique ARMOR study, which for more than 10 years has tracked antibiotic resistance patterns specific to pathogens that affect the eye,” Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb, said in a company news release. “Bausch + Lomb will continue to remain focused on conducting research that will help us develop new products and medicines to address the evolving needs of customers and patients.”

Following is a complete list of titles and lead authors for each of these posters:

• “Antibiotic Resistance Among Ocular Pathogens—an Update from the 2022 ARMOR study.” Sanfilippo et al.
• “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
• “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
• “Evaluation of Color Perception and Contrast Acuity of Novel UV Light-Filtering Material for IOLs as Compared to Yellow-Tinted Blue light Filtering lenses.” Kolesnitchenko et al.
• “Evaluation of Enhanced Monofocal Plus IOLs with Extended Depth of Focus.” Lau et al.
• “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
• “Long‐term Safety and Efficacy of NOV03 (Perfluorohexyloctane) for the Treatment of Patients with Dry Eye Disease associated with Meibomian Gland Dysfunction: The Kalahari Study.” Vittitow et al.
• “Spectroscopic Characterization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease.” Borchman et al.